

13 April 2010

ASX / MEDIA RELEASE

MEDICAL AUSTRALIA AND ANALYTICA SIGN LICENSING AND DISTRIBUTION AGREEMENT FOR AUSTRALIA, NEW ZEALAND, UK, EU, ASIA AND MIDDLE EAST

- **Multifaceted agreement including the manufacture, regulatory sponsorship and marketing of the Analytica AutoStart® Burette device and AutoFlush feature.**
- **Exclusive distribution opportunity encompassing Australia, New Zealand and UK, with springboard into Asia, Middle East and EU.**
- **Long-term strategic alliance to form product development, commercialisation and distribution partnership.**

Sydney, 12 April 2010: Medical products manufacturer and distributor Medical Australia Limited (ASX: MLA), formerly BMDI TUTA Limited, today announced that it has signed a licensing and distribution agreement with Analytica Limited (ASX: ALT), a leading Australian medical technology company focussing on the development and commercialisation of a range of medical devices and pharmaceutical implants.

Under the terms of the agreement, Medical Australia will exclusively distribute Analytica's flagship AutoStart® Burette and AutoFlush products, initially into the Australian, New Zealand and UK markets, with a view to expanding into key Asian, Middle Eastern and European markets. Medical Australia will also act as manufacturer and regulatory sponsor of the Analytica products.

Additionally, Medical Australia and Analytica have agreed to partner on the development of new medical devices, where Analytica will act as product developer and IP owner, with Medical Australia providing regulatory, manufacturing, marketing and distribution support.

The AutoStart® Burette is a unique infusion device that automatically restarts the delivery of intravenous fluid once the burette has dispensed its predetermined amount of liquid or drug. Automatic restart of the IV fluid, once the drug is dispensed, can provide enormous savings in nursing time during and following a medication event.

In March, the AutoStart® Burette was granted Pre-market Notification (510(k)) clearance by the US Food and Drug Administration, which allows the product to be legally supplied in the United States and its Territories. The combination of TGA, FDA, and CE clearances is a strong foundation on which the AutoStart Burette may be supplied to the world's major markets.

Medical Australia's CEO, Mr. Mark Donnison said, "We are excited to be partnering with Analytica on this agreement and to be collaborating to bring new products to market. We have been impressed with Analytica's excellent reputation, and the fact that they are a medical products innovator means there are great synergies with our own core clinical competencies. Their products line up with our TUTA range of products that has been a leader in medical plastics for more than 60 years.

"This partnership is again further evidence that the investment we have made in our Supply Chain is starting to deliver results. Analytica has recognised that Medical Australia has the manufacturing and distribution capability to successfully deliver their product to customers in local and global markets".

Analytica's Chairman Dr. Michael Monsour said that the agreement with Medical Australia gives Analytica an immediate and comprehensive distribution platform for its AutoStart® and AutoFlush technologies. "Our decision to partner with Medical Australia is based on the strength of their supply chain and the fact that it gives us an immediate go-to-market solution for our flagship products. This deal offers significant upside to our ongoing product development and commercialisation initiatives.

"It is a great opportunity to combine our respective skills to develop leading products for the global medical market."

Medical Australia and Analytica expect the AutoStart® Burette and AutoFlush products to enter Medical Australia's supply chain during the coming months.

Mark Donnison
Chief Executive Officer, Medical Australia
Ph: +61 2 9466 5300

Dr Michael Monsour
Chairman, Analytica
Ph: +61 7 3278 1950

ENDS

